Clinical Trials Browser

Phase 2 × Hodgkin Disease × galiximab × Clear all

NCT00516217 2016-07-06

Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2 Completed

30 enrolled 9 charts

Hodgkin Disease, Lymphoma